Skip NavigationSkip to Content
Return Return to Search Results

Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles

  1. Author:
    Chandler, Morgan
    Jain, Sankalp
    Halman, Justin
    Hong, Enping
    Dobrovolskaia,Marina
    Zakharov, Alexey V
    Afonin, Kirill A [ORCID]

  2. Author Address

    Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC, 28223, USA., National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA., Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.,
    1. Year: 2022
    2. Date: Oct 10
    3. Epub Date: 2022 10 10
  2. Journal: Small (Weinheim an der Bergstrasse, Germany)
    1. Pages: e2204941
  4. Type of Article: Article
  5. Article Number: e2204941
  1. Abstract:

    Nucleic acid nanoparticles, or NANPs, rationally designed to communicate with the human immune system, can offer innovative therapeutic strategies to overcome the limitations of traditional nucleic acid therapies. Each set of NANPs is unique in their architectural parameters and physicochemical properties, which together with the type of delivery vehicles determine the kind and the magnitude of their immune response. Currently, there are no predictive tools that would reliably guide the design of NANPs to the desired immunological outcome, a step crucial for the success of personalized therapies. Through a systematic approach investigating physicochemical and immunological profiles of a comprehensive panel of various NANPs, the research team developes and experimentally validates a computational model based on the transformer architecture able to predict the immune activities of NANPs. It is anticipated that the freely accessible computational tool that is called an "artificial immune cell," or AI-cell, will aid in addressing the current critical public health challenges related to safety criteria of nucleic acid therapies in a timely manner and promote the development of novel biomedical tools. © 2022 The Authors. Small published by Wiley-VCH GmbH.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/smll.202204941
  3. PMID: 36216772

Library Notes

  1. Fiscal Year: FY2022-2023
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel